The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.
Pharmacological approaches to the treatment of ARDS are reviewed. Future treatments should be targeted at elements of the pathological process that produce specific clinical problems.
Cranshaw
J
J
Unit of Critical Care, NHLI Division, Imperial College of Science, Technology & Medicine and Royal Brompton Hospital, London SW3 6NP, UK.
Griffiths
M J D
MJ
Evans
T W
TW
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D003422:Critical Care; D011464:Epoprostenol / Q000627:therapeutic use; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D016859:Lipoxygenase Inhibitors; D009569:Nitric Oxide / Q000008:administration & dosage; D010712:Phosphatidic Acids / Q000037:antagonists & inhibitors; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012128:Respiratory Distress Syndrome / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014665:Vasodilator Agents / Q000008:administration & dosage
D000305:Adrenal Cortex Hormones; D000975:Antioxidants; D016859:Lipoxygenase Inhibitors; D010712:Phosphatidic Acids; D011459:Prostaglandins E, Synthetic; D011663:Pulmonary Surfactants; D014665:Vasodilator Agents; D009569:Nitric Oxide; D011464:Epoprostenol; D013930:Thromboxane-A Synthase